Keratea

Plants featuring:

High production capacity and manufacturing flexibility across state-of-the-art facilities.
Technological excellence and innovation.
A strong manufacturing base with a clear international focus.

NEW Plant I in Keratea

Total area: 10,000 m²
Manufacturing of 25 million pMDIs
Manufacturing of 1.2 billion tablets
500 employees
Activity focused on the production and development of inhalation products (for asthma and chronic obstructive pulmonary disease) and solid forms (cardiological, antihypertensives, respiratory and central nervous system diseases, antibiotics).
2 manufacturing units which, when operating at full capacity (3 shifts/day), can produce 50,000,000 packages annually.

UNIQUE in Greece and one of 4 in Europe dedicated to pMDIs manufacturing.

NEW Plant II in Keratea (2028 - 2029)

Total area: 8,000 m²
Manufacturing of 1.3 billion tablets
>300 employees
Activity focusing on the production and development of medicines in tablet form (cardiological, antihypertensives, central nervous system diseases and antibiotics).
3 manufacturing units which, when operating at full capacity (3 shifts/day), can produce 30,000,000 packages annually.

ELPEN can serve more than 10,000,000 patients in Greece & abroad